Lynch syndrome is characterized by the development of microsatellite-instable cancers that share neoantigens, offering an opportunity for targeted immunotherapy. NOUS-209 is a heterologous prime-boost cancer vaccine in clinical development, employing viral vectors encoding 209 shared neoantigen peptides derived from frameshift mutations (FSM) commonly found in microsatellite-instable tumors. In this study, we investigated the presence and dynamics of NOUS-209 targeted FSMs in both primary and metachronous Lynch syndrome-associated cancers. Whole-exome sequencing was performed for 73 tumors, including 58 colorectal cancers and 15 urothelial cancers, from 58 individuals with confirmed Lynch syndrome. A median of 57 FSMs per colorectal cancer and 24 FSMs per urothelial cancer were observed, with similar FSM burdens in both primary and metachronous tumors. Analysis of nine matched primary-metachronous tumor pairs revealed evidence of immune editing: FSMs predicted to encode highly immunogenic neoepitopes were selectively lost in metachronous tumors, whereas those with lower predicted immunogenicity were retained. Importantly, all subsequent primary cancers acquired novel FSMs encoding neoantigens with strong predicted HLA-binding affinity, supporting the rationale for NOUS-209-mediated immune interception. These findings demonstrated that NOUS-209 FSMs are present in both colorectal cancers and urothelial cancers in Lynch syndrome, expanding the therapeutic potential of NOUS-209 beyond colorectal cancer. Moreover, the emergence of novel targetable FSMs in metachronous tumors suggests that NOUS-209 immunotherapy may be effective in the prevention of both primary and metachronous Lynch syndrome-associated cancers.
OBJECTIVE:The optimal treatment of keloid scars remains unclear. Current protocols advise treatment with triamcinolone injection, when applicable, and surgery followed by adjuvant radiotherapy. However, the dosage and treatment modality of the radiotherapy vary among centres. This retrospective case series evaluated the long-term results of a single institution regarding keloid treatment using surgical excision, adjuvant external radiotherapy with site-dependent dosage, and wound site immobilisation with surgical tape and pressure treatment. METHOD:A review of the patient registry from Tampere University Hospital, Finland, between the years 2010 and 2018 was conducted. A total of 73 keloids on 58 patients were excised, followed by a site-dependent dose of external radiotherapy with electron beam therapy (EBT). The mean follow-up time was 19.6 months. RESULTS:In total, 91.8% of the keloids were in remission at the end of follow-up, resulting in a 8.2% recurrence rate detected at 19.6 months on average. The highest recurrence rate-at 15%-was detected in the earlobe, which received the lowest level of irradiation according to the author's protocol. CONCLUSION:The results suggest that surgical excision with adjuvant EBT is highly efficient for keloid treatment in adult patients, and should be considered the first option in keloid treatment whenever excision is feasible. The recurrence rate of earlobe keloids with the current lower dose of EBT was higher than previously published and warrants further investigation.
To assess the effects of anticoagulant use on the treatment of hip fracture and post-operative rehabilitation in geriatric population. The use of antithrombotics was associated with delayed mobilization and the need for plural blood transfusions. Direct oral anticoagulants and ADP inhibitors were also associated with delayed surgery and longer length of stay. Antithrombotics may delay hip fracture management, highlighting the importance of enabling early mobilization for optimal functional outcomes. Early surgical treatment is important to allow a prompt start for rehabilitation after hip fracture. In patients using antithrombotic drugs, the surgery is often delayed, but it is unclear how this affects early post-operative recovery. The course of treatment and early post-operative outcomes of hip fracture patients, aged ≥ 70 years, using either warfarin, direct oral anticoagulants (DOACs), or adenosine diphosphate. (ADP) inhibitors were compared to age- and sex-matched controls not using such drugs, operated during the same observation period at the same hospital. All data were retrospectively collected from electronic medical records. 306 patients (53
Study Design.Retrospective registry study.Objective.To investigate the influence of depressive symptoms on return to work (RTW) after lumbar spine fusion (LSF) surgery over a two-year follow-up. A secondary objective was to evaluate the development of depressive symptoms separately in patients who succeeded or failed to RTW after surgery.Background.Depressive symptoms are overrepresented in patients undergoing LSF surgery. The effect of depressive symptoms on RTW after LSF surgery has not yet been widely studied.Materials and Methods.A total of 348 consecutive patients available to the workforce underwent LSF surgery. Depressive symptoms were evaluated at baseline and three, 12, and 24 months postoperatively using the MHI-5. Lower scores have been shown to indicate greater depressive symptoms, and a cutoff score of <= 68 indicates current major depressive disorder (MDD). Cumulative RTW and MHI-5 scores were prospectively followed up at the aforementioned time points.Results.Before surgery, almost half (46%) of the patients had MDD. The presence of preoperative MDD indicated a lower RTW at two years [72% vs. 82%, adjusted HR: 0.77 (95% CI: 0.61 to 0.98)]. The probability of RTW was correlated with an increase in the MHI-5 score until the inflection point of 70, after which a further increase in the MHI-5 score no longer increased the probability of RTW. In addition, the MHI-5 score was significantly higher than baseline at three months postoperatively [13 points (95% CI: 10 to 15)] and remained higher in patients who RTW during two years. However, only a marginal increase in MHI-5 was observed in those who failed to RTW. This finding indicates fewer depressive symptoms in patients who successfully RTW.Conclusion.Patients with preoperative MDD were less likely to RTW after LSF surgery. After surgery, depressive symptoms diminished in the group who did successfully RTW.Level of Evidence.Level III.
PURPOSE:Although the association between cytotoxic T lymphocytes and favorable prognosis in colorectal cancer is well established, the prognostic significance of B lymphocytes remains more ambiguous. This study aimed to assess the characteristics and significance of various B-cell and plasma cell subsets in colorectal tumors. EXPERIMENTAL DESIGN:We designed a seven-plex IHC assay, combined with machine learning-based image analysis, to identify various B-cell and plasma cell populations and applied it to study a cohort of 912 colorectal tumors. We assessed the prognostic significance of B-cell and plasma cell densities using Kaplan-Meier estimators and Cox regression models. Additionally, we designed a more clinically applicable three-plex assay, which we used to study B-cell and plasma cell densities in a separate validation cohort of 737 patients. RESULTS:High plasma cell density in the center of the tumor was associated with longer cancer-specific survival independent of disease stage, mismatch repair status, T-cell densities, and other covariates. In the study cohort, the multivariable HR for high (vs. low) plasma cell density was 0.48 (95% confidence interval, 0.32-0.72; Ptrend = 0.0005), whereas the corresponding HR in the validation cohort was 0.37 (95% confidence interval, 0.21-0.65; Ptrend = 0.0003). Of the specific subsets, IgG1-IgG2- plasma cells showed the strongest association with improved survival. High B-cell densities were not independently associated with a better prognosis. CONCLUSIONS:Plasma cell densities in the center of the tumor represent a relevant tumor-immune biomarker in colorectal cancer, complementing T-cell density measurements.